Canagliflozin and Stroke in Type 2 Diabetes Mellitus: Results from the Randomized CANVAS Program Trials

Stroke

Volumn 50, Issue 2, 2019, Pages 396-404

  Zhou, Zien ^a,b   Lindley, Richard I ^c   Rådholm, Karin ^c,d   Jenkins, Bronwyn ^e   Watson, John ^a   Perkovic, Vlado ^a,c   Mahaffey, Kenneth W ^f   De Zeeuw, Dick ^g   Fulcher, Greg ^c   Shaw, Wayne ^h   Oh, Richard ^h   Desai, Mehul ^h   Matthews, David R ⁱ   Neal, Bruce ^a,c,j  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c UNIVERSITY OF SYDNEY   (Australia)

^d LINKÖPING UNIVERSITY   (Sweden)

^e ROYAL NORTH SHORE HOSPITAL   (Australia)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^h JANSSEN RESEARCH AND DEVELOPMENT   (United States)

ⁱ UNIVERSITY OF OXFORD   (United Kingdom)

^j IMPERIAL COLLEGE LONDON   (United Kingdom)

more..

Author keywords

canagliflozin; cardiovascular diseases; diabetes mellitus, type 2; ischemic attack, transient; stroke

Indexed keywords

ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANAGLIFLOZIN; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TRANSIENT ISCHEMIC ATTACK; CLINICAL TRIAL; COMPLICATION; DIABETIC COMPLICATION; MIDDLE AGED; MORTALITY; MULTICENTER STUDY;

AGED; CANAGLIFLOZIN; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; STROKE;

EID: 85060644234     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.118.023009     Document Type: Article

References (23)

1. Chen L, Magliano DJ, Zimmet PZ, The worldwide epidemiology of type 2 diabetes mellitus-present and future perspectives. Nat Rev Endocrinol 2011 8 228 236. doi: 10.1038/nrendo.2011.183
2. Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, IRIS Trial Investigators Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 2016 374 1321 1331. doi: 10.1056/NEJMoa1506930
3. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, SUSTAIN-6 Investigators Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016 375 1834 1844. doi: 10.1056/NEJMoa1607141
4. Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013 159 262 274. doi: 10.7326/0003-4819-159-4-201308200-00007
5. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, EMPA-REG OUTCOME Investigators Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015 373 2117 2128. doi: 10.1056/NEJMoa1504720
6. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, CANVAS Program Collaborative Group Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017 377 644 657. doi: 10.1056/NEJMoa1611925
7. Zinman B, Inzucchi SE, Lachin JM, Wanner C, Fitchett D, Kohler S, EMPA-REG OUTCOME Investigators (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) Empagliflozin and cerebrovascular events in patients with type 2 diabetes mellitus at high cardiovascular risk. Stroke 2017 48 1218 1225. doi: 10.1161/STROKEAHA.116.015756
8. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di AE, Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010 375 2215 2222. doi: 10.1016/S0140-6736(10)60484-9
9. Neal B, Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Stein P, Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-a randomized placebo-controlled trial. Am Heart J 2013 166 217.e11 223.e11. doi: 10.1016/j.ahj.2013.05.007
10. Neal B, Perkovic V, Matthews DR, Mahaffey KW, Fulcher G, Meininger G, CANVAS-R Trial Collaborative Group Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): a randomized, placebo-controlled trial. Diabetes Obes Metab 2017 19 387 393. doi: 10.1111/dom.12829
11. Neal B, Perkovic V, Mahaffey KW, Fulcher G, Erondu N, Desai M, CANVAS Program collaborative group Optimizing the analysis strategy for the CANVAS Program: a prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials. Diabetes Obes Metab 2017 19 926 935. doi: 10.1111/dom.12924
12. Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ, Culebras A, American Heart Association Stroke Council, Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; Council on Peripheral Vascular Disease; Council on Nutrition, Physical Activity and Metabolism An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013 44 2064 2089. doi: 10.1161/STR.0b013e318296aeca
13. Lawes CM, Rodgers A, Bennett DA, Parag V, Suh I, Ueshima H, Asia Pacific Cohort Studies Collaboration Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens 2003 21 707 716. doi: 10.1097/01.hjh.0000052492.18130.07
14. Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, CANVAS Program Collaborative Group Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation 2018 137 323 334. doi: 10.1161/CIRCULATIONAHA.117.032038
15. Jardine MJ, Mahaffey KW, Neal B, Agarwal R, Bakris GL, Brenner BM, CREDENCE study Investigators The Canagliflozin and Renal Endpoints in Diabetes With Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics. Am J Nephrol 2017 46 462 472. doi: 10.1159/000484633
16. Turnbull F, Blood Pressure Lowering Treatment Trialists' Collaboration Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003 362 1527 1535. doi: 10.1016/S0140-6736(03)14739-3
17. Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J, Blood Pressure Lowering Treatment Trialists' Collaboration Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005 165 1410 1419. doi: 10.1001/archinte.165.12.1410
18. PROGRESS Collaborative Group Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001 358 1033 1041. doi: 10.1016/S0140-6736(01)06178-5
19. Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 2016 387 435 443. doi: 10.1016/S0140-6736(15)00805-3
20. Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A, Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 2015 313 603 615. doi: 10.1001/jama.2014.18574
21. Malyszko J, Muntner P, Rysz J, Banach M, Blood pressure levels and stroke: J-curve phenomenon? Curr Hypertens Rep 2013 15 575 581. doi: 10.1007/s11906-013-0402-z
22. Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB, Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 2014 8 262.e9 275.e9. doi: 10.1016/j.jash.2014.01.007
23. Inzucchi SE, Zinman B, Wanner C, Ferrari R, Fitchett D, Hantel S, SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res 2015 12 90 100. doi: 10.1177/1479164114559852